Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221760 · ClinicalTrials.gov registry record · Phase 1
Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation
A Phase 1 study, sponsored by n-Lorem Foundation.
- Active
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT07221760 is a Phase 1 study that is active but no longer recruiting, run by n-Lorem Foundation. The registered enrollment target is 1 participants.
The verdict
NCT07221760, a Phase 1 study, is active but no longer recruiting, sponsored by n-Lorem Foundation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with dentatorubral-pallidoluysian atrophy (DRPLA) due to a heterozygous pathogenic CAG trinucleotide expansion in ATN1
Interventions
- DRUG nL-ATN1-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2025-11-06 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221760
The ClinicalTrials.gov registry entry for NCT07221760 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is n-Lorem Foundation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nL-ATN1-001 is the first listed.
NCT07221760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07221760 about?
NCT07221760 is a clinical study titled "Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation". This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with dentatorubral-pallidoluysian atrophy (DRPLA) due to a heterozygous pathogenic CAG trinucleotide expansion in ATN1
What is the current status of trial NCT07221760?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2025-11-06. Estimated completion is 2027-11.
What interventions are being tested in trial NCT07221760?
The interventions under investigation include: nL-ATN1-001 (DRUG).
Who is sponsoring clinical trial NCT07221760?
This trial is sponsored by n-Lorem Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.